Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 4/2015

01-04-2015 | Original Article—Liver, Pancreas, and Biliary Tract

Possible involvement of Toll-like receptor 7 in the development of type 1 autoimmune pancreatitis

Authors: Yuri Fukui, Kazushige Uchida, Yutaku Sakaguchi, Toshiro Fukui, Akiyoshi Nishio, Nobuaki Shikata, Noriko Sakaida, Yoshiko Uemura, Sohei Satoi, Kazuichi Okazaki

Published in: Journal of Gastroenterology | Issue 4/2015

Login to get access

Abstract

Background

High serum immunoglobulin G4 (IgG4) levels and IgG4-positive plasma cell infiltration are characteristic of type 1 autoimmune pancreatitis (AIP). It is unclear whether innate immunity is a cause of type 1 AIP; the possible involvement of microbial infection has been suggested in its pathogenesis. To clarify the pathogenesis of type 1 AIP, we investigated Toll-like receptors (TLRs) in type 1 AIP patients.

Methods

We studied nine cases of type 1 AIP with ten cases of alcoholic chronic pancreatitis (ACP) and three of the samples from non-tumorous lesion of neuroendocrine tumor (NET) as control subjects. We counted the number of TLR1-11-positive cells immunohistochemically stained with anti-TLR1-11 antibodies. To identify TLR-positive cells in pancreata from type 1 AIP patients, we used a double-immunofluorescence method and counted the numbers of identifiable CD68-, CD163-, CD123-, and CD20-positive cells.

Results

In type 1 AIP, TLR7 (8.815 ± 1.755), TLR8 (3.852 ± 1.489), and TLR10 (3.852 ± 0.921) were highly expressed. Only the ratio of TLR7 per monocyte was significantly higher in type 1 AIP (0.053 ± 0.012) than in ACP (0.007 ± 0.004; p < 0.01) and non-tumorous lesion of NET (0.000 ± 0.000; p < 0.01). In type 1 AIP, the CD163 to TLR7 ratio (0.789 ± 0.031) was significantly higher both than that of CD123 to TLR7 ratio (0.034 ± 0.006; p < 0.001) and CD20 to TLR7 ratio (0.029 ± 0.010; p < 0.001).

Conclusions

TLR7 might be key pattern-recognition receptors involved in the development of type 1 AIP.
Literature
1.
Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.CrossRefPubMed
2.
Kawaguchi K, Koike M, Tsuruta K, et al. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22:387–95.CrossRefPubMed
3.
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.CrossRefPubMed
4.
Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.CrossRefPubMed
5.
Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982–4.CrossRefPubMed
6.
Ito T, Nakano I, Koyanagi S, et al. Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Dig Dis Sci. 1997;42:1458–68.CrossRefPubMed
7.
Horiuchi A, Kawa S, Akamatsu T, et al. Characteristic pancreatic duct appearance in autoimmune chronic pancreatitis: a case report and review of the Japanese literature. Am J Gastroenterol. 1998;93:260–3.CrossRefPubMed
8.
Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol. 2000;95:2788–94.CrossRefPubMed
9.
Okazaki K, Uchida K, Chiba T. Recent concept of autoimmune-related pancreatitis. J Gastroenterol. 2001;36:293–302.CrossRefPubMed
10.
Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445:552–63.CrossRefPubMed
11.
Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27:1119–27.CrossRefPubMed
12.
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.CrossRefPubMed
13.
Okazaki K, Kawa S, Kamisawa T, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2010;45:249–65.CrossRefPubMed
14.
Ota M, Katsuyama Y, Hamano H, et al. Two critical genes (HLA-DRB1 and ABCF1) in the HLA region are associated with the susceptibility to autoimmune pancreatitis. Immunogenetics. 2007;59:45–52.CrossRefPubMed
15.
Umemura T, Ota M, Hamano H, Katsuyama Y, et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol. 2008;103:588–94.CrossRefPubMed
16.
Umemura T, Ota M, Hamano H, et al. Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut. 2006;55:1367–8.CrossRefPubMedCentralPubMed
17.
Zen Y, Fujii T, Harada K, Kawano M, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45:1538–46.CrossRefPubMed
18.
Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator- and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis. Pancreas. 2011;40:1120–30.CrossRefPubMed
19.
Watanabe T, Yamashita K, Fujikawa S, et al. Involvement of activation of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum. 2012;64:914–24.CrossRefPubMed
20.
Watanabe T, Yamashita K, Sakurai T, et al. Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol. 2013;48:247–53.CrossRefPubMed
21.
22.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.CrossRefPubMed
23.
Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819–26.CrossRefPubMed
24.
25.
26.
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–84.CrossRefPubMed
27.
Koyabu M, Uchida K, Miyoshi H, et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol. 2010;45:732–41.CrossRefPubMed
28.
29.
30.
31.
32.
Bunnell CE, Monif GR. Interstitial pancreatitis in the congenital rubella syndrome. J Pediatr. 1972;80:465–6.CrossRefPubMed
33.
34.
Rizzardi GP, Tambussi G, Lazzarin A. Acute pancreatitis during primary HIV-1 infection. N Engl J Med. 1997;336:1836–7.CrossRefPubMed
35.
Blum A, Podvitzky O, Shalabi R, et al. Acute pancreatitis may be caused by H1N1 influenza A virus infection. Isr Med Assoc J. 2010;12:640–1.PubMed
36.
Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008;223:271–83.CrossRefPubMed
37.
38.
Umemura T, Katsuyama Y, Hamano H, et al. Association analysis of Toll-like receptor 4 polymorphisms with autoimmune pancreatitis. Hum Immunol. 2009;70:742–6.CrossRefPubMed
39.
Meagher C, Tang Q, Fife BT, et al. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008;180:7793–803.CrossRefPubMedCentralPubMed
40.
41.
Vallance BA, Hewlett BR, Snider DP, et al. T cell-mediated exocrine pancreatic damage in major histocompatibility complex class II-deficient mice. Gastroenterology. 1998;115:978–87.CrossRefPubMed
42.
Tsubata R, Tsubata T, Hiai H, et al. Autoimmune disease of exocrine organs in immunodeficient alymphoplasia mice: a spontaneous model for Sjögren’s syndrome. Eur J Immunol. 1996;26:2742–8.CrossRefPubMed
43.
Hosaka N, Nose M, Kyogoku M, et al. Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+ mice. Proc Natl Acad Sci USA. 1996;93:8558–62.CrossRefPubMedCentralPubMed
44.
Kanno H, Nose M, Itoh J, et al. Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism. Clin Exp Immunol. 1992;89:68–73.CrossRefPubMedCentralPubMed
45.
Watanabe S, Suzuki K, Kawauchi Y, et al. Kinetic analysis of the development of pancreatic lesions in mice infected with a murine retrovirus. Clin Immunol. 2003;109:212–23.CrossRefPubMed
46.
Suzuki K, Makino M, Okada Y, et al. Exocrinopathy resembling Sjögren’s syndrome induced by a murine retrovirus. Lab Invest. 1993;69:430–5.PubMed
47.
Qu WM, Miyazaki T, Terada M, et al. A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid. Clin Exp Immunol. 2002;129:27–34.CrossRefPubMedCentralPubMed
48.
Yamashina M, Nishio A, Nakayama S, et al. Comparative study on experimental autoimmune pancreatitis and its extrapancreatic involvement in mice. Pancreas. 2012;41:1255–62.CrossRefPubMed
49.
Nishio A, Asada M, Uchida K, et al. The role of innate immunity in the pathogenesis of experimental autoimmune pancreatitis in mice. Pancreas. 2011;40:95–102.CrossRefPubMed
50.
Asada M, Nishio A, Akamatsu T, et al. Analysis of humoral immune response in experimental autoimmune pancreatitis in mice. Pancreas. 2010;39:224–31.CrossRefPubMed
51.
Soga Y, Komori H, Miyazaki T, et al. Toll-like receptor 3 signaling induces chronic pancreatitis through the Fas/Fas ligand-mediated cytotoxicity. Tohoku J Exp Med. 2009;217:175–84.CrossRefPubMed
52.
Haruta I, Yanagisawa N, Kawamura S, et al. A mouse model of autoimmune pancreatitis with salivary gland involvement triggered by innate immunity via persistent exposure to avirulent bacteria. Lab Invest. 2010;90:1757–69.CrossRefPubMed
53.
Masamune A, Kikuta K, Watanabe T, et al. Pancreatic stellate cells express Toll-like receptors. J Gastroenterol. 2008;43:352–62.CrossRefPubMed
54.
Sharif R, Dawra R, Wasiluk K, et al. Impact of Toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut. 2009;58:813–9.CrossRefPubMed
55.
Ding SQ, Li Y, Zhou ZG, et al. Toll-like receptor 4-mediated apoptosis of pancreatic cells in cerulein-induced acute pancreatitis in mice. Hepatobiliary Pancreat Dis Int. 2010;9:645–50.PubMed
56.
Hoque R, Sohail M, Malik A, et al. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology. 2011;141:358–69.CrossRefPubMedCentralPubMed
57.
Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005;23:1399–405.CrossRefPubMed
58.
Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531–7.CrossRefPubMed
59.
Gantier MP, Tong S, Behlke MA, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol. 2008;180:2117–24.CrossRefPubMed
60.
Greena NM, Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol. 2011;23:106–12.CrossRef
61.
Chamberlain ND, Kim SJ, Vila OM, et al. Ligation of TLR7 by rheumatoid arthritis synovial fluid single-strand RNA induces transcription of TNFα in monocytes. Ann Rheum Dis. 2013;72:418–26.CrossRefPubMedCentralPubMed
62.
Reed JH, Jain M, Lee K, et al. Complement receptor 3 influences Toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem. 2013;29(288):9077–83.CrossRef
63.
Shikhagaie MM, Andersson CK, Mori M, et al. Mapping of TLR5 and TLR7 in central and distal human airways and identification of reduced TLR expression in severe asthma. Clin Exp Allergy. 2014;44:184–96.CrossRefPubMed
64.
65.
Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.CrossRefPubMed
66.
Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47:1650–60.CrossRefPubMed
67.
Detlefsen S, Sipos B, Zhao J, et al. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol. 2008;32:986–95.CrossRefPubMed
68.
Notohara K, Wani Y, Fujisawa M. Proliferation of CD163+ spindle-shaped macrophages in IgG4-related sclerosing disease: analysis of lymphoplasmacytic sclerosing pancreatitis and sclerosing sialadenitis. Mod Pathol. 2010;23:367A.CrossRef
69.
Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009;27:3330–7.CrossRefPubMed
70.
Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423–30.CrossRefPubMed
71.
Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein–Barr virus status in classical Hodgkin’s lymphoma. Haematologica. 2011;96:269–76.CrossRefPubMedCentralPubMed
72.
Maniecki MB, Moller HJ, Moestrup SK, et al. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology. 2006;211:407–17.CrossRefPubMed
73.
74.
Sung SA, Jo SK, Cho WY, et al. Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. Nephron Exp Nephrol. 2007;105:e1–9.CrossRefPubMed
75.
Kitamoto K, Machida Y, Uchida J, et al. Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci. 2009;111:285–92.CrossRefPubMed
76.
Cheever AW, Williams ME, Wynn TA, et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol. 1994;153:753–9.PubMed
77.
Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest. 1999;104:777–85.CrossRefPubMedCentralPubMed
78.
Reiman RM, Thompson RW, Feng CG, et al. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun. 2006;74:1471–9.CrossRefPubMedCentralPubMed
79.
Balmelli C, Alves MP, Steiner E, et al. Responsiveness of fibrocytes to Toll-like receptor danger signals. Immunobiology. 2007;212:693–9.CrossRefPubMed
80.
Pulskens WP, Rampanelli E, Teske GJ, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol. 2010;21:1299–308.CrossRefPubMedCentralPubMed
81.
82.
Braga TT, Correa-Costa M, Guise YF, et al. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med. 2012;18:1231–9.CrossRefPubMedCentralPubMed
83.
Uchida K, Okazaki K, Nishi T, et al. Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin. Lab Invest. 2002;82:411–24.CrossRefPubMed
84.
85.
Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naïve and CD4 + CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008;36:133–40.CrossRefPubMed
Metadata
Title
Possible involvement of Toll-like receptor 7 in the development of type 1 autoimmune pancreatitis
Authors
Yuri Fukui
Kazushige Uchida
Yutaku Sakaguchi
Toshiro Fukui
Akiyoshi Nishio
Nobuaki Shikata
Noriko Sakaida
Yoshiko Uemura
Sohei Satoi
Kazuichi Okazaki
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 4/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-0977-4

Other articles of this Issue 4/2015

Journal of Gastroenterology 4/2015 Go to the issue

Original Article—Alimentary Tract

Epithelial-derived nuclear IL-33 aggravates inflammation in the pathogenesis of reflux esophagitis

Review

NSAID enteropathy and bacteria: a complicated relationship

Special Article

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Original Article—Liver, Pancreas, and Biliary Tract

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Letter to the Editor

Response to the letter by Brotherton regarding “Insoluble fiber and intestinal microbiota metabolism”

Review

Small bowel injury in low-dose aspirin users
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits